About this item:

747 Views | 495 Downloads

Author Notes:

Correspondence to: W. Robert Taylor, MD, PhD, Division of Cardiology, Emory University School of Medicine, 101 Woodruff Circle, Suite 319 WMB, Atlanta, GA 30322. E-mail: wtaylor@emory.edu

Drs Levit and Landázuri contributed equally to this article.

We thank Dr. Emir Veledar for his assistance with the statistical analysis.

Subjects:

Research Funding:

This work was supported by a gift from Jake Aronov.

Keywords:

  • angiogenesis
  • cardiovascular diseases
  • heart failure
  • ischemia
  • myocardial infarction

Cellular Encapsulation Enhances Cardiac Repair

Show all authors Show less authors

Tools:

Journal Title:

Journal of the American Heart Association

Volume:

Volume 2, Number 5

Publisher:

Type of Work:

Article | Final Publisher PDF

Abstract:

Background Stem cells for cardiac repair have shown promise in preclinical trials, but lower than expected retention, viability, and efficacy. Encapsulation is one potential strategy to increase viable cell retention while facilitating paracrine effects. Methods and Results Human mesenchymal stem cells (hMSC) were encapsulated in alginate and attached to the heart with a hydrogel patch in a rat myocardial infarction (MI) model. Cells were tracked using bioluminescence (BLI) and cardiac function measured by transthoracic echocardiography (TTE) and cardiac magnetic resonance imaging (CMR). Microvasculature was quantified using von Willebrand factor staining and scar measured by Masson's Trichrome. Post‐MI ejection fraction by CMR was greatly improved in encapsulated hMSC‐treated animals (MI: 34±3%, MI+Gel: 35±3%, MI+Gel+hMSC: 39±2%, MI+Gel+encapsulated hMSC: 56±1%; n=4 per group; P<0.01). Data represent mean±SEM. By TTE, encapsulated hMSC‐treated animals had improved fractional shortening. Longitudinal BLI showed greatest hMSC retention when the cells were encapsulated (P<0.05). Scar size at 28 days was significantly reduced in encapsulated hMSC‐treated animals (MI: 12±1%, n=8; MI+Gel: 14±2%, n=7; MI+Gel+hMSC: 14±1%, n=7; MI+Gel+encapsulated hMSC: 7±1%, n=6; P<0.05). There was a large increase in microvascular density in the peri‐infarct area (MI: 121±10, n=7; MI+Gel: 153±26, n=5; MI+Gel+hMSC: 198±18, n=7; MI+Gel+encapsulated hMSC: 828±56 vessels/mm2, n=6; P<0.01). Conclusions Alginate encapsulation improved retention of hMSCs and facilitated paracrine effects such as increased peri‐infarct microvasculature and decreased scar. Encapsulation of MSCs improved cardiac function post‐MI and represents a new, translatable strategy for optimization of regenerative therapies for cardiovascular diseases. Keywords: angiogenesis, cardiovascular diseases, heart failure, ischemia, myocardial infarction

Copyright information:

© 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell

This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).

Creative Commons License

Export to EndNote